
Novartis Venture Fund and Hikma Ventures are set to exit the online medical treatment provider in a cash-and-stock purchase by 23andme.
The digital therapeutics developer closed a series B round that included corporate venturing units and existing investors Hikma Ventures and Sanofi Ventures.
Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the immunotherapy developer.
Online insurance provider Justos raised $35.8m in a SoftBank-led series A round while social game studio GreenPark Sports closed a $31m series B that included Alameda Research.
Takeda, Merck & Co, Ipsen and Merck Group all scored exits as the immuno-oncology drug developer floated at the bottom of its IPO range.
Blue Venture Fund and CVS Health Ventures helped the telemedicine system developer raise funding which will boost its expansion into new markets and expand its treatment offering.
Leverage Health Solution, Cigna Ventures and Leaps by Bayer helped the skin condition treatment developer hike its total funding to approximately $67m.
Pfizer and Sanofi helped the precision medicine developer close a series B round which will be used to advance and expand its pipeline of respiratory disease drug candidates.
Sumitomo Mitsui’s DS Asset Management subsidiary backed the neurological and metabolic disorder drug developer in a round that will support clinical trials.
Eli Lilly, WuXi AppTec and Schrodinger were among the investors in the cardiovascular, pulmonary and metabolic disorder drug developer's latest round.